Connection
Martin Cannon to Receptor, erbB-2
This is a "connection" page, showing publications Martin Cannon has written about Receptor, erbB-2.
|
|
Connection Strength |
|
|
|
|
|
0.201 |
|
|
|
-
Yu Y, Pilgrim P, Zhou W, Gagliano N, Frezza EE, Jenkins M, Weidanz JA, Lustgarten J, Cannon M, Bumm K, Cobos E, Kast WM, Chiriva-Internati M. rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol. 2008 Dec; 21(4):435-42.
Score: 0.080
-
Bellone S, Palmieri M, Gokden M, Joshua J, Roman JJ, Pecorelli S, Cannon MJ, Santin AD. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol. 2003 Oct; 91(1):231-40.
Score: 0.056
-
Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002 May; 8(5):1271-9.
Score: 0.051
-
Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther. 2004 Aug; 4(4):679-89.
Score: 0.015
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|